Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA

Selby, N.M. (Nicholas M.); Blankestijn, P.J. (Peter J.); Boor, P. (Peter); Combe, C. (Christian); Eckardt, K.U. (Kai-Uwe); Eikefjord, E. (Eli); Garcia-Fernandez, N. (Nuria); Golay, X. (Xavier); Gordon, I. (Isky); Grenier, N. (Nicolas); Hockings, P.D. (Paul D.); Jensen, J.D. (Jens D.); Joles, J.A. (Jaap A.); Kalra, P.A.(Philip A.); Krämer, B.K. (Bernhard K.); Mark, P.B. (Patrick B.); Mendichovszky, I.A. (Iosif A.); Nikolic, O. (Olivera); Odudu, A. (Aghogho); Ong, A.C.M. (Albert C. M.); Ortiz, A. (Alberto); Pruijm, M. (Menno); Remuzzi, G. (Giuseppe); Rorvik, J. (Jarle); Seigneux, S. (Sophie); Simms, R.J. (Roslyn J.); Slatinska, J. (Janka); Summers, P. (Paul); Taal, M. (Maarten W.); Thoeny, H.C. (Harriet C.); Vallée, J.P. (Jean-Paul); Wolf, M. (Marcos); Caroli, A. (Anna); Sourbron, S. (Steven)

Keywords:

Biomarker
Chronic kidney disease
Fibrosis
Inflammation
MRI

Issue Date:

2018

Publisher:

Oxford University Press

Project:

115974 - BEAt-DKD - Biomarker Enterprise to Attack DKD - Sofia ref.: 115974

ISSN:

0931-0509

Note:

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation:

Selby, N.M. (Nicholas M.); Blankestijn, P.J. (Peter J.); Boor, P. (Peter); et al. "Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA". Nephrology dialysis transplantation. 33 (Supl.2), 2018, ii4 - ii14

Abstract

Functional renal magnetic resonance imaging (MRI) has seen a number of recent advances, and techniques are now available that can generate quantitative imaging biomarkers with the potential to improve the management of kidney disease. Such biomarkers are sensitive to changes in renal blood flow, tissue perfusion, oxygenation and microstructure (including inflammation and fibrosis), processes that are important in a range of renal diseases including chronic kidney disease. However, several challenges remain to move these techniques towards clinical adoption, from technical validation through biological and clinical validation, to demonstration of cost-effectiveness and regulatory qualification. To address these challenges, the European Cooperation in Science and Technology Action PARENCHIMA was initiated in early 2017. PARENCHIMA is a multidisciplinary pan-European network with an overarching aim of eliminating the main barriers to the broader evaluation, commercial exploitation and clinical use of renal MRI biomarkers. This position paper lays out PARENCHIMA’s vision on key clinical questions that MRI must address to become more widely used in patients with kidney disease, first within research settings and ultimately in clinical practice. We then present a series of practical recommendations to accelerate the study and translation of these techniques.

URI:

https://hdl.handle.net/10171/65736

DOI:

10.1093/ndt/gfy152

Appears in Collections:

DA - CUN - Nefrología - Artículos de revista

Files in This Item: